ES499224A0 - Un procedimiento de produccion de derivados de fenetilamina sulfamoil-sustituidos - Google Patents

Un procedimiento de produccion de derivados de fenetilamina sulfamoil-sustituidos

Info

Publication number
ES499224A0
ES499224A0 ES499224A ES499224A ES499224A0 ES 499224 A0 ES499224 A0 ES 499224A0 ES 499224 A ES499224 A ES 499224A ES 499224 A ES499224 A ES 499224A ES 499224 A0 ES499224 A0 ES 499224A0
Authority
ES
Spain
Prior art keywords
fenetilamine
sulfamoil
derivatives
substituted
procedure
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES499224A
Other languages
English (en)
Other versions
ES8201966A1 (es
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yamanouchi Pharmaceutical Co Ltd
Original Assignee
Yamanouchi Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=11859488&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES499224(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Yamanouchi Pharmaceutical Co Ltd filed Critical Yamanouchi Pharmaceutical Co Ltd
Publication of ES8201966A1 publication Critical patent/ES8201966A1/es
Publication of ES499224A0 publication Critical patent/ES499224A0/es
Granted legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D203/00—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D203/04—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D203/06—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D203/08—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring nitrogen atom
    • C07D203/10—Radicals substituted by singly bound oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
ES499224A 1980-02-08 1981-02-06 Un procedimiento de produccion de derivados de fenetilamina sulfamoil-sustituidos Granted ES499224A0 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP1438280A JPS56110665A (en) 1980-02-08 1980-02-08 Sulfamoyl-substituted phenetylamine derivative and its preparation

Publications (2)

Publication Number Publication Date
ES8201966A1 ES8201966A1 (es) 1982-01-01
ES499224A0 true ES499224A0 (es) 1982-01-01

Family

ID=11859488

Family Applications (1)

Application Number Title Priority Date Filing Date
ES499224A Granted ES499224A0 (es) 1980-02-08 1981-02-06 Un procedimiento de produccion de derivados de fenetilamina sulfamoil-sustituidos

Country Status (17)

Country Link
US (6) US4373106A (es)
EP (1) EP0034432B1 (es)
JP (1) JPS56110665A (es)
AR (2) AR227533A1 (es)
AT (1) ATE7223T1 (es)
AU (1) AU541720B2 (es)
CA (1) CA1177849A (es)
DE (2) DE3163257D1 (es)
ES (1) ES499224A0 (es)
GR (1) GR73827B (es)
IE (1) IE50862B1 (es)
LU (1) LU90000I2 (es)
MX (2) MX6859E (es)
NL (1) NL950014I2 (es)
PT (1) PT72460B (es)
SU (3) SU1082320A3 (es)
UA (3) UA5981A1 (es)

Families Citing this family (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5391825A (en) * 1980-02-08 1995-02-21 Yamanouchi Pharmaceutical Co., Ltd. Sulfamoyl substituted phenethylamine intermediates
JPS56110665A (en) * 1980-02-08 1981-09-01 Yamanouchi Pharmaceut Co Ltd Sulfamoyl-substituted phenetylamine derivative and its preparation
EP0091749A3 (en) * 1982-04-08 1984-12-05 Beecham Group Plc Ethanolamine derivatives, process for their preparation and pharmaceutical compositions containing them
US4772475A (en) * 1985-03-08 1988-09-20 Yamanouchi Pharmaceutical Co., Ltd. Controlled-release multiple units pharmaceutical formulation
JPS62114952A (ja) * 1985-11-13 1987-05-26 Yamanouchi Pharmaceut Co Ltd 置換フエネチルアミン誘導体の製造法
JPH066565B2 (ja) * 1986-07-21 1994-01-26 山之内製薬株式会社 光学活性なベンゼンスルホンアミド誘導体の製造法
US4971990A (en) 1988-02-19 1990-11-20 Hokuriku Pharmaceutical Co., Ltd. Phenoxyethylamine derivatives, for preparing the same and composition for exhibiting excellent α1 -blocking activity containing the same
IE64061B1 (en) * 1989-09-04 1995-07-12 Yamanouchi Pharma Co Ltd External preparation containing amusulosin
US5288759A (en) * 1992-08-27 1994-02-22 Alcon Laboratories, Inc. Use of certain sulfamoyl-substituted phenethylamine derivatives to reverse drug-induced mydriasis
AU7085194A (en) * 1993-07-14 1995-02-13 Yamanouchi Pharmaceutical Co., Ltd. Remedy for urination disorder accompanying prostatic hypertrophy
FR2737494B1 (fr) * 1995-08-04 1997-08-29 Synthelabo Derives de benzenesulfonamide, leur preparation et leur application en therapeutique
US6177430B1 (en) 1997-03-27 2001-01-23 Pfizer Inc Use of α1-adrenoreceptor antagonists in the prevention and treatment of benign prostatic hyperplasia
BR9708656A (pt) * 1996-04-12 2000-01-04 Beth Israel Hospital Barra suplementar para diabéticos
US6410554B1 (en) 1998-03-23 2002-06-25 Merck & Co., Inc. Combination therapy for the treatment of benign prostatic hyperplasia
EP1075486A1 (en) * 1998-05-06 2001-02-14 Duke University Method of treating bladder and lower urinary tract syndromes
TW536402B (en) 1998-06-26 2003-06-11 Yamanouchi Pharma Co Ltd Pharmaceutical composition for the therapy of voiding dysfunction
HUP0104493A3 (en) 1998-09-30 2002-12-28 Takeda Pharmaceutical Drugs for improving vesical excretory strength
AR022348A1 (es) * 1999-08-09 2002-09-04 Astellas Pharma Inc Una composicion farmaceutica para el tratamiento de los sintomas del tracto urinario inferior
IL141235A (en) * 2000-02-09 2012-04-30 Novartis Int Pharm Ltd Combined use of an alpha-adrenoceptor antagonist and a muscarinic antagonist in the preparation of a drug for the treatment of non-malignant prostatic hyperplasia
US20020035107A1 (en) 2000-06-20 2002-03-21 Stefan Henke Highly concentrated stable meloxicam solutions
US20020065286A1 (en) * 2000-08-21 2002-05-30 Davies Michael John Treatment of wounds
US20020091129A1 (en) * 2000-11-20 2002-07-11 Mitradev Boolell Treatment of premature ejaculation
JP2001288115A (ja) * 2001-02-07 2001-10-16 Yamanouchi Pharmaceut Co Ltd 下部尿路症治療剤
KR100421508B1 (ko) * 2001-08-07 2004-03-09 김정한 항균 및 항진균 활성을 갖는 신규한 펜에틸아민 유도체와이의 염
US6835853B2 (en) 2001-10-31 2004-12-28 Synthon Bv Process for resolution of tamsulosin and compounds, compositions, and processes associated therewith
NL1021822C2 (nl) * 2001-11-07 2003-07-15 Synthon Bv Tamsulosinetabletten.
DE10161077A1 (de) 2001-12-12 2003-06-18 Boehringer Ingelheim Vetmed Hochkonzentrierte stabile Meloxicamlösungen zur nadellosen Injektion
US20030229001A1 (en) * 2002-01-31 2003-12-11 Pfizer Inc. Treatment of male sexual dysfunction
AU2003217676B2 (en) 2002-02-22 2009-06-11 Takeda Pharmaceutical Company Limited Active agent delivery systems and methods for protecting and administering active agents
DK1501517T3 (da) 2002-04-24 2007-06-11 Boehringer Ingelheim Pharma Farmaceutisk kombination til behandling af godartet hyperplasia af prostata eller til langtidsforhindring af akut urinretention
US6894188B1 (en) * 2002-04-30 2005-05-17 Ranbaxy Laboratory Limited Tamsulosin derivative
ES2200699B1 (es) * 2002-07-12 2005-10-01 Ragactives, S.L Procedimiento para la separacion de r(-) y s(+)-5-(2-((2-(etoxifenoxi)etil)amino)propil-2-metoxibenceno-sulfonamida.
WO2004016582A1 (en) * 2002-08-14 2004-02-26 Natco Pharma Limited An improved process for the preparation of tamsulosin hydrochloride
JP3835763B2 (ja) 2002-08-19 2006-10-18 ファイザー・プロダクツ・インク 増殖亢進疾患のための組み合わせ治療
GB0219961D0 (en) 2002-08-28 2002-10-02 Pfizer Ltd Oxytocin inhibitors
US8992980B2 (en) 2002-10-25 2015-03-31 Boehringer Ingelheim Vetmedica Gmbh Water-soluble meloxicam granules
US7018658B2 (en) 2002-11-14 2006-03-28 Synthon Bv Pharmaceutical pellets comprising tamsulosin
US7323462B2 (en) * 2002-12-10 2008-01-29 Pfizer Inc. Morpholine dopamine agonists
WO2004054560A1 (en) 2002-12-13 2004-07-01 Warner-Lambert Company Llc Alpha-2-delta ligand to treat lower urinary tract symptoms
CA2451267A1 (en) * 2002-12-13 2004-06-13 Warner-Lambert Company Llc Pharmaceutical uses for alpha2delta ligands
EP1603866B1 (en) * 2002-12-26 2009-04-29 Cadila Healthcare Limited A process for the preparation of enantiomerically pure (r) or (s)-5-(2-aminopropyl)-2-methoxybenzenesulfonamide
KR100503639B1 (ko) 2003-02-12 2005-07-26 보령제약 주식회사 탐술로신의 정제 방법
PA8597401A1 (es) * 2003-03-14 2005-05-24 Pfizer Derivados del acido 3-(1-[3-(1,3-benzotiazol-6-il) propilcarbamoil] cicloalquil) propanoico como inhibidores de nep
DE10315702A1 (de) * 2003-04-07 2004-10-28 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von Arzneitmittelkombinationen zur Behandlung von gutartiger Prostatahyperplasie oder zur Behandlung von abakterieller Prostatitis
US20040220186A1 (en) * 2003-04-30 2004-11-04 Pfizer Inc. PDE9 inhibitors for treating type 2 diabetes,metabolic syndrome, and cardiovascular disease
WO2004106299A2 (en) * 2003-05-30 2004-12-09 Ranbaxy Laboratories Limited Substituted pyrrole derivatives and their use as hmg-co inhibitors
US20050065158A1 (en) * 2003-07-16 2005-03-24 Pfizer Inc. Treatment of sexual dysfunction
US7291640B2 (en) * 2003-09-22 2007-11-06 Pfizer Inc. Substituted triazole derivatives as oxytocin antagonists
US20050106253A1 (en) * 2003-11-13 2005-05-19 Platteeuw Johannes J. Pharmaceutical pellets comprising tamsulosin
CA2451175A1 (en) * 2003-11-26 2005-05-26 Torcan Chemical Ltd. Process for the preparation of tamsulosin
US7329780B2 (en) * 2003-12-09 2008-02-12 Cj Corporation Method of preparing optically pure phenethylamine derivatives
SI21655A (sl) * 2003-12-29 2005-06-30 LEK farmacevtska dru�ba d.d. Sinteza optično čistega (R)-5-(2-aminopropil)-2-metoksibenzensulfonamida
SI21656A (sl) * 2003-12-29 2005-06-30 LEK farmacevtska družba d.d. Priprava (R)-5-(2-(2-(2-etoksifenoksi) etilamino)-1-propil)-2-metoksibenzensulfonamida hidroklorida z visoko kemijsko čistoto
EP1568369A1 (en) 2004-02-23 2005-08-31 Boehringer Ingelheim Vetmedica Gmbh Use of meloxicam for the treatment of respiratory diseases in pigs
US20050267096A1 (en) * 2004-05-26 2005-12-01 Pfizer Inc New indazole and indolone derivatives and their use pharmaceuticals
US20050288270A1 (en) * 2004-05-27 2005-12-29 Pfizer Inc New aminopyridine derivatives and their use as pharmaceuticals
WO2006004093A1 (ja) * 2004-07-07 2006-01-12 Hamari Chemicals, Ltd. 光学活性フェニルプロピルアミン誘導体の製法
CN100545148C (zh) 2004-08-16 2009-09-30 神隆新加坡私人有限公司 一种抗良性***肥大药物坦索罗辛之合成方法
US7238839B2 (en) 2004-10-07 2007-07-03 Divi's Laboratories Limited Process for the resolution of racemic (R,S) -5-(2-(2-(2- ethoxyphenoxy) ethylamino)Propyl)-2-methoxybenzene sulfonamide (tamsulosin), its novel R and S isomers and their salts and processes for their preparation
PT103216B (pt) * 2004-12-06 2010-05-19 Hovione Farmaciencia S A Preparação de tamsulosin
US20060128719A1 (en) * 2004-12-13 2006-06-15 Boehringer Ingelheim Pharmaceuticals, Inc. Use of alpha-adrenergic blockers for the treatment of dysmenorrhea
ES2258394B1 (es) * 2004-12-31 2007-12-01 Quimica Sintetica, S.A. Procedimiento enzimatico para la preparacion de un compuesto intermedio y su uso en la sintesis de tamsulosina clorhidrato.
JP2008533193A (ja) * 2005-03-21 2008-08-21 ファイザー・リミテッド オキシトシン拮抗薬としての置換トリアゾール誘導体
US7618972B2 (en) * 2005-03-21 2009-11-17 Pfizer Inc Substituted triazole derivatives as oxytocin antagonists
AR057290A1 (es) * 2005-05-04 2007-11-28 Medichem Sa Proceso para la preparacion de tamsulosina
US20090137844A1 (en) * 2005-06-15 2009-05-28 Fermion Oy Crystallization process
CA2618103A1 (en) * 2005-08-10 2007-02-15 Pfizer Limited Substituted triazole derivatives as oxytocin antagonists
GT200600381A (es) 2005-08-25 2007-03-28 Compuestos organicos
US8273918B2 (en) * 2005-09-12 2012-09-25 Avrobindo Pharma Ltd. Process for preparing tamsulosin hydrochloride
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
WO2007054896A1 (en) * 2005-11-08 2007-05-18 Ranbaxy Laboratories Limited Process for (3r, 5r)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4- [(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3, 5-dihydroxy-heptanoic acid hemi calcium salt
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
US8383660B2 (en) 2006-03-10 2013-02-26 Pfizer Inc. Dibenzyl amine compounds and derivatives
US7919506B2 (en) 2006-03-10 2011-04-05 Pfizer Inc. Dibenzyl amine compounds and derivatives
WO2008020314A2 (en) * 2006-03-14 2008-02-21 Ranbaxy Laboratories Limited Statin stabilizing dosage formulations
EP2026766A1 (en) 2006-05-17 2009-02-25 Synthon B.V. Tablet composition with a prolonged release of tamsulosin
RU2009105089A (ru) * 2006-07-14 2010-08-27 Ранбакси Лабораториз Лимитед (In) ПОЛИМОРФНЫЕ ФОРМЫ ГМГ-КоА-РЕДУКТАЗЫ И ИХ ПРИМЕНЕНИЕ
CN101547696A (zh) * 2006-08-08 2009-09-30 奥斯拜客斯制药有限公司 具有α肾上腺素能阻断效应的取代喹唑啉化合物的制备和应用
US20080113030A1 (en) * 2006-11-09 2008-05-15 Ching-Fen Hsiao Sustained release tamsulosin formulations
CN101190890B (zh) 2006-11-30 2011-04-27 江苏豪森药业股份有限公司 5-[(2r)-[2-[2-[2-(2,2,2-三氟乙氧基)苯氧基]乙基]氨基]丙基]-2-甲氧基苯磺酰胺
ES2382009T3 (es) 2006-12-01 2012-06-04 Bristol-Myers Squibb Company Derivados de N-((3-bencil)-2,2-(bis-fenil-)-propan-1-amina como inhibidores de CETP para el tratamiento de aterosclerosis y enfermedades cardiovasculares
US20080312328A1 (en) * 2007-06-14 2008-12-18 Protia, Llc Deuterium-enriched tamsulosin
US20090004284A1 (en) * 2007-06-26 2009-01-01 Watson Pharmaceuticals, Inc. Controlled release tamsulosin hydrochloride formulation
CN101754760A (zh) * 2007-07-20 2010-06-23 安斯泰来制药株式会社 用以改善伴随着***肥大的下尿路症状的药物组合物
US20100261770A1 (en) 2007-12-21 2010-10-14 Astellas Pharma Inc. Pharmaceutical composition for improving lower urinary tract symptoms
EP2181707A1 (en) 2008-11-04 2010-05-05 Astellas Ireland Co., Ltd. Combined use of an alpha-adrenergic receptor antagonist and an anti-muscarinic agent
US8465770B2 (en) 2008-12-24 2013-06-18 Synthon Bv Low dose controlled release tablet
HUE029638T2 (en) 2009-02-04 2017-03-28 Astellas Pharma Inc Pharmaceutical preparation for oral administration
EP2255793A1 (en) 2009-05-28 2010-12-01 Krka Tovarna Zdravil, D.D., Novo Mesto Pharmaceutical composition comprising tamsulosin
IN2012DN03157A (es) 2009-10-12 2015-09-18 Boehringer Ingelheim Vetmed
CN102050766B (zh) * 2009-11-03 2013-08-07 安徽省新星药物开发有限责任公司 一种盐酸氨磺洛尔的合成方法
US9149480B2 (en) 2010-03-03 2015-10-06 Boehringer Ingeleheim Vetmedica GmbH Use of meloxicam for the long-term treatment of musculoskeletal disorders in cats
US9795568B2 (en) 2010-05-05 2017-10-24 Boehringer Ingelheim Vetmedica Gmbh Low concentration meloxicam tablets
WO2012110092A1 (en) 2011-02-17 2012-08-23 Synthon Bv Tamsulosin derivatives
BR112015026513A2 (pt) 2013-04-17 2017-07-25 Pfizer derivados de n-piperidin-3-ilbenzamida para tratar as doenças cardiovasculares
BR102013020508B1 (pt) 2013-08-12 2021-01-12 Ems S/A. Forma de dosagem que compreende um inibidor de esteroide 5-alfa-redutase e um bloqueador alfa, processo para a preparaçãode uma forma de dosagem e uso da forma de dosagem
ES2555485T1 (es) 2014-05-26 2016-01-04 Galenicum Health S.L. Composiciones farmacéuticas que contienen un agente activo
WO2016055901A1 (en) 2014-10-08 2016-04-14 Pfizer Inc. Substituted amide compounds
CN106478467B (zh) * 2016-10-13 2018-07-13 深圳万和制药有限公司 制备稳定的盐酸坦索罗辛的方法
EP4035660A1 (en) 2017-10-17 2022-08-03 Synthon B.V. Tablets comprising tamsulosin and solifenacin
EP3473244A1 (en) 2017-10-20 2019-04-24 Veru Inc. Controlled release oral tamsulosin hydrochloride
EP3473245A1 (en) 2017-10-20 2019-04-24 Veru Inc. Controlled release oral tamsulosin hydrochloride
CN108037196B (zh) * 2017-11-23 2020-06-23 中山奕安泰医药科技有限公司 一种3-硝基-4-[[(四氢-2h-吡喃-4-基)甲基]氨基]苯磺酰胺的检测方法
EA202191892A1 (ru) 2019-01-18 2022-02-24 Астразенека Аб Ингибиторы pcsk9 и способы их применения

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3701808A (en) * 1967-12-21 1972-10-31 Allen & Hanburys Ltd Phenylethanolamines
SE368197B (es) * 1968-11-18 1974-06-24 Pfizer
US3878212A (en) * 1970-04-28 1975-04-15 Clemens Rufer Blood sugar lowering sulfamoyl pyrimidines and asymmetrical carbon atom
US4137328A (en) * 1970-07-18 1979-01-30 Pfizer Inc. Phenyl-alkanolamine, alkylamine and α-aminoalkyl ketone derivatives as heart stimulants
US3711545A (en) * 1971-02-23 1973-01-16 Smith Kline French Lab Alpha-aminoalkyl-4-hydroxy-3-sulfamoylaminobenzyl alcohols
DE2115926C3 (de) * 1971-04-01 1978-05-03 C.H. Boehringer Sohn, 6507 Ingelheim 1 -(4-Hydroxy-3-dimethylaminosuIfamidophenyI)-2-aminoäthanderivate, Verfahren zu ihrer Herstellung und diese enthaltende Mittel
US3860647A (en) * 1973-08-20 1975-01-14 Smithkline Corp {60 -Aminomethyl-4-hydroxy-3-sulfamyl-benzyl alcohols and 4-hydroxy-3-sulfamyl phenethylamines
GB1593651A (en) * 1977-02-03 1981-07-22 Allen & Hanburys Ltd Amides
CA1147342A (en) * 1977-10-12 1983-05-31 Kazuo Imai Process of producing novel phenylethanolamine derivatives
JPS5553262A (en) * 1978-10-17 1980-04-18 Yamanouchi Pharmaceut Co Ltd Phenylethanolamine derivative
JPS5553261A (en) * 1978-10-17 1980-04-18 Yamanouchi Pharmaceut Co Ltd New phenylethanolamine derivative and its preparation
JPS606330B2 (ja) * 1978-11-30 1985-02-18 山之内製薬株式会社 α・β両遮断剤
JPS56110665A (en) * 1980-02-08 1981-09-01 Yamanouchi Pharmaceut Co Ltd Sulfamoyl-substituted phenetylamine derivative and its preparation
US4558156A (en) * 1980-02-08 1985-12-10 Yamanouchi Pharmaceutical Co., Ltd. Sulfamoyl-substituted phenethylamine derivatives
DE3110573A1 (de) * 1981-03-18 1982-10-21 Bayer Ag, 5090 Leverkusen Verfahren zur herstellung von n- und o-substituierten di- und/oder polyurethanen
JPS5950671B2 (ja) * 1982-08-26 1984-12-10 山之内製薬株式会社 フェニルエタノ−ルアミン誘導体およびその製造法
US4558106A (en) * 1983-03-29 1985-12-10 Union Carbide Corporation Polymerization process using metal formate to reduce the color of thermoplastic copolymers

Also Published As

Publication number Publication date
DE19675042I2 (de) 2001-06-13
ES8201966A1 (es) 1982-01-01
NL950014I1 (nl) 1996-12-02
AR230433A1 (es) 1984-04-30
SU1248533A3 (ru) 1986-07-30
LU90000I2 (fr) 1997-03-04
ATE7223T1 (de) 1984-05-15
DE3163257D1 (en) 1984-05-30
UA5981A1 (uk) 1994-12-29
US4868216A (en) 1989-09-19
GR73827B (es) 1984-05-04
PT72460A (en) 1981-03-01
US4703063A (en) 1987-10-27
JPS56110665A (en) 1981-09-01
UA5980A1 (uk) 1994-12-29
AU541720B2 (en) 1985-01-17
MX6859E (es) 1986-09-08
US4761500A (en) 1988-08-02
EP0034432A2 (en) 1981-08-26
IE50862B1 (en) 1986-08-06
US4987152A (en) 1991-01-22
AR227533A1 (es) 1982-11-15
EP0034432A3 (en) 1982-03-24
UA5990A1 (uk) 1994-12-29
MX9203592A (es) 1992-07-31
US4731478A (en) 1988-03-15
NL950014I2 (nl) 1997-01-06
SU1181540A3 (ru) 1985-09-23
CA1177849A (en) 1984-11-13
PT72460B (en) 1982-02-04
AU6689681A (en) 1981-08-13
US4373106A (en) 1983-02-08
JPS6252742B2 (es) 1987-11-06
EP0034432B1 (en) 1984-04-25
IE810236L (en) 1981-08-08
SU1082320A3 (ru) 1984-03-23

Similar Documents

Publication Publication Date Title
ES499224A0 (es) Un procedimiento de produccion de derivados de fenetilamina sulfamoil-sustituidos
ES509659A0 (es) Un procedimiento para la produccion de un derivado de carbostirilo
ES503502A0 (es) Un procedimiento para la produccion de un derivado de pripe-razina.
ES508490A0 (es) "un metodo de produccion de derivados de tiazolidina".
ES499401A0 (es) Un procedimiento para la produccion de compuestos de tria- ril-metano
IT1144744B (it) Procedimento per la produzione di solfobetaine
ES496980A0 (es) Un procedimiento para la produccion de un derivado de benza-mida
ES504927A0 (es) Un proceso para la preparacion de derivados de n-alquilimi- dazoles sustituidos
ES525245A0 (es) Proceso de produccion de los derivados de la piperacina
ES507939A0 (es) Un procedimiento de preparacion de nuevos derivados de la hidroxifenil-tetrahidropiridina .
ES499303A0 (es) Un procedimiento de preparacion de derivados bencilidenicos
AR229471A1 (es) Procedimiento de preparacion de un derivado de alcoxi-carbonilhexil-metoxifenil piperazina
IT1170744B (it) Procedimento per la produzione di o-trimetil-sililcellulose
ES505372A0 (es) Un metodo de preparar derivados de fenil-piperazina
ES502593A0 (es) Un procedimiento para la produccion de halogenuros de alco- xi-acilcarnitina
ES486832A0 (es) Un procedimiento de produccion de derivados de 7 -metoxice- falosporina
RO83972A (ro) Procedeu de preparare a derivatilor de oxazafosfarine
RO80172A2 (ro) Procedeu de elaborare a ferotitanului
TR21803A (tr) Atese dayanikh krommagnezi ueruenlerinin ueretilmesine mahsus usul
AR226104A1 (es) Un procedimiento de preparacion de terc-butilfenoles
IT1170745B (it) Procedimento per la produzione di o-trimetilsilicellulose
IT1141061B (it) Procedimento per la produzione di uricasi
ES506858A0 (es) Un procedimiento de preparacion de derivados de triazoloqui-nazolinona.
IT1195275B (it) Procedimento per la produzione di un polisaccaride
ES504282A0 (es) Un procedimiento para la produccion de un derivado de tilo- sina